Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

Shields has been vocal about women's wellness and now backs an initiative for women to be aware of an infection that's ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.